Quantitation of Productively Infected Monocytes and Macrophages of Simian Immunodeficiency Virus-Infected Macaques

Claudia R. Avalos, Sarah L. Price, Ellen R. Forsyth, Julia N. Pin, Erin N. Shirk, Brandon T. Bullock, Suzanne E. Queen, Ming Li, Dane Gellerup, Shelby L. O’Connor, M. Christine Zink, Joseph L. Mankowski, Lucio Gama, Janice E. Clements

Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine, Madison, Wisconsin, USA

ABSTRACT

Despite the success of combined antiretroviral therapy (ART), human immunodeficiency virus (HIV) infection remains a lifelong infection because of latent viral reservoirs in infected patients. The contribution of CD4+ T cells to infection and disease progression has been extensively studied. However, during early HIV infection, macrophages in brain and other tissues are infected and contribute to tissue-specific diseases, such as encephalitis and dementia in brain and pneumonia in lung. The extent of infection of monocytes and macrophages has not been rigorously assessed with assays comparable to those used to study infection of CD4+ T cells and to evaluate the number of CD4+ T cells that harbor infectious viral genomes. To assess the contribution of productively infected monocytes and macrophages to HIV- and simian immunodeficiency virus (SIV)-infected cells in vivo, we developed a quantitative virus outgrowth assay (QVOA) based on similar assays used to quantify CD4+ T cell latent reservoirs in HIV- and SIV-infected individuals in whom the infection is suppressed by ART. Myeloid cells expressing CD11b were serially diluted and cocultured with susceptible cells to amplify virus. T cell receptor β RNA was measured as a control to assess the potential contribution of CD4+ T cells in the assay. Virus production in the supernatant was quantitated by quantitative reverse transcription-PCR. Productively infected myeloid cells were detected in blood, bronchoalveolar lavage fluid, lungs, spleen, and brain, demonstrating that these cells persist throughout SIV infection and have the potential to contribute to the viral reservoir during ART.

IMPORTANCE

Infection of CD4+ T cells and their role as latent reservoirs have been rigorously assessed; however, the frequency of productively infected monocytes and macrophages in vivo has not been similarly studied. Myeloid cells, unlike lymphocytes, are resistant to the cytopathic effects of HIV. Moreover, tissue-resident macrophages have the ability to self-renew and persist in the body for months to years. Thus, tissue macrophages, once infected, have the characteristics of a potentially stable viral reservoir. A better understanding of the number of productively infected macrophages is crucial to further evaluate the role of infected myeloid cells as a potential viral reservoir. In the study described here we compared the frequency of productively infected CD4+ T cells and macrophages in an SIV-infected macaque model. We developed a critical assay that will allow us to quantify myeloid cells containing viral genomes that lead to productive infection in SIV-infected macaques and assess the role of macrophages as potential reservoirs.

Lentiviruses infect myeloid lineage cells in tissues, and these cells are responsible for the multiorgan disease characteristic of infection with this family of retroviruses (1–3). Human immunodeficiency virus (HIV) was the first primate lentivirus identified that infects CD4+ T cells as well as myeloid cells in the blood and tissues of infected individuals (4–6). HIV infects myeloid cells in lymph nodes, spleen, heart, lungs, the peripheral nervous system, and the central nervous system (CNS) (7–11). The HIV genome encodes genes that specifically interact and/or interfere with restriction factors present in myeloid cells, providing evolutionary evidence that HIV replication in myeloid cells is important for virus replication and pathogenesis in vivo (12).

Myeloid cells were thought to be terminally differentiated cells with a limited life span. However, recent studies have demonstrated that resident tissue macrophages are capable of self-renewal and that monocytes from blood differentiate into distinct macrophage phenotypes after entering tissues (13, 14). Moreover, tissue-resident macrophages, such as alveolar macrophages, splenic red pulp macrophages, and microglia, are derived from embryonic yolk sac progenitor cells that self-renew with little to no contribution from circulating monocytes during homeostasis (15–18). Furthermore, HIV- and simian immunodeficiency virus (SIV)-infected macrophages are not efficiently killed by CD8+ T cells like infected CD4+ T cells are (19, 20). Thus, resident tissue macrophages remain in tissues long term, are relatively resistant to
the cytopathic effects of HIV infection compared to CD4+ T cells, and may serve as stable viral reservoirs.

SIV-infected macaques have been used to study the pathogenesis of SIV in vivo and have been used as models of HIV infection in humans. Like HIV, SIV infects both CD4+ T cells and macrophages in blood, tissues, and brain (21–25). Our laboratories developed and characterized a consistent, accelerated SIV-infected macaque model resulting in AIDS and CNS disease (in ~80% of macaques) in 3 months, which is shorter than the course of disease pathogenesis and frequency of CNS disease in other models of SIV infection (21). Another model used to study CNS infection used depletion of CD8+ T cells in SIV-infected macaques, which resulted in the increased accumulation of infected macrophages in the CNS and a heightened severity of neurological disease, suggesting that infection of macrophages plays a key role in CNS disease (26).

The frequency of HIV or SIV infection of macrophages in tissues has previously been examined in a number of studies (27, 28). Infection is quantified by measuring the amount of viral DNA in cells isolated from tissues; however, this approach overestimates the number of productively infected CD4+ T cells due to the presence of a large proportion of defective proviruses in vivo (29, 30). A more rigorous approach to the quantification of cells that harbor replication-competent virus is the quantitative viral outgrowth assay (QVOA), which quantitates the number of HIV-infected resting CD4+ T cells that produce infectious virus (31–33). This assay has been used to quantify the number of resting CD4+ lymphocytes in vivo in HIV-infected individuals on antiretroviral therapy (ART) that harbor replication-competent viral genomes and serves as one of the major assays for studying viral latency in that cell type (29, 31).

Using a QVOA that our laboratories developed for SIV-infected nonhuman primate CD4+ T cells, we previously demonstrated that the number of infected resting CD4+ T cells in the blood and tissues of macaques in which SIV infection was suppressed by ART was equivalent to the number of infected resting CD4+ T cells in HIV-infected humans on ART (31–35). In this study, we developed a novel macrophage QVOA (Mφ-QVOA) to assess the frequency of productively SIV-infected monocytes (in blood) and macrophages (in tissues) using a well-characterized SIV-infected macaque model (36–38). To determine the potential contribution of CD4+ T cells to the quantitation of macrophages, we also assessed the number of CD3+ T cells in each assay by measuring the amount of T cell receptor β (TCRβ) RNA.

Using the myeloid Mφ-QVOA, we show that during chronic SIV infection, productively infected monocytes or macrophages are present in blood, bronchoalveolar lavage (BAL) fluid, lungs, spleen, and brain. This assay can also be used to quantify myeloid cells productively infected with HIV and SIV that may contribute to viral persistence and latency in ART-treated humans and macaques.

**MATERIALS AND METHODS**

**Animal studies.** Fourteen juvenile pigtailed macaques (Pms; *Macaca nemestrina*) were inoculated intravenously with the SIV/ΔδB670 swarm and the macrophage-tropic clone SIV/17E-Fr as previously described (36, 38, 39). One macaque (Pm11) was treated at 12 days postinoculation (dpi) with 12.5 mg flucloxacillin and 5 mg paroxetine once per day orally and euthanized at ~80 dpi as previously described (40). Three macaques (Pm12, Pm13, and Pm14) were treated at 28 days prior to virus inoculation with 2 mg minocycline/kg of body weight twice per day orally and were euthanized during asymptomatic infection (~35 dpi). These macaques were added to the study to investigate macrophage infection at different times after infection. These treatments did not affect either the plasma viral load or disease progression (40). Eleven macaques were euthanized during late-stage infection (50 to 87 dpi), and three macaques were euthanized during chronic infection (34 to 36 dpi) (Table 1). Blood and cerebrospinal fluid (CSF) samples were collected longitudinally postinfection. When macaques were euthanized, they were perfused with sterile saline to remove blood and circulating virus as described elsewhere (35). Viral loads in plasma and CSF, CD4+ T cell counts in blood, and viral RNA loads in tissues were determined for all macaques in the study (Table 1). To assess the extent of CNS inflammation and pathology, brain tissue was evaluated as previously described and the degree of inflammation was scored on a scale ranging from none to severe (38). These studies were performed in accordance with federal guidelines and institutional

**TABLE 1 Detailed characterization of the SIV-infected macaques used in the study**

| Animal identifier | Duration of infection (days) | CNS score | Cell count (no. of cells/µl blood) | Viral load(no. of SIV copies/ml) | Tissue viral load (no. of SIV copies/µg tissue RNA) |
|-------------------|-----------------------------|-----------|-----------------------------------|-------------------------------|-----------------------------------------------|
|                   |                             |           | CD4+ T cells | Monocytes | Plasma | CSF | Parietal cortex | Basal ganglion | Lung | Spleen |
| Pm1               | 62                          | Severe    | 166 | 1,271 | 6.50E+07 | 9.85E+06 | 5.65E+06 | 4.10E+06 | 74.02 | 2.59E+06 |
| Pm2               | 60                          | Severe    | 57  | 45   | 8.38E+07 | 2.43E+07 | 1.30E+06 | 1.11E+06 | 99.46 | 675,000  |
| Pm3               | 50                          | Severe    | 113 | 1,022 | 4.24E+07 | 4.98E+06 | 826,254 | 1.55E+06 | 503,785 | 1.22E+06 |
| Pm4               | 84                          | Severe    | 52  | 4,333 | 1.49E+09 | 1.14E+07 | 4.63E+06 | 1.92E+06 | 1,543 | 1.61E+07 |
| Pm5               | 86                          | Mild      | 222 | 243  | 1.18E+07 | 1.84E+07 | 1.48E+06 | 807,774  | 247   | 1.19E+07 |
| Pm6               | 85                          | None      | 396 | 525  | 3.65E+08 | 166,022  | 699     | 10,632  | 1,197 | 8.45E+06 |
| Pm7               | 83                          | None      | 418 | 767  | 1.05E+07 | 117,088  | 22      | 14,995  | 332   | 8.68E+06 |
| Pm8               | 79                          | None      | 56  | 416  | 2.20E+06 | 129,536  | ND      | ND      | 129   | 5.51E+06 |
| Pm9               | 87                          | None      | 464 | 874  | 1.25E+06 | 112,867  | ND      | ND      | 152   | 4.40E+06 |
| Pm10              | 84                          | None      | 693 | 1,071 | 300,229  | 12,150   | ND      | ND      | 1,797 | 204,000  |
| Pm11              | 84                          | None      | 119 | 612  | 651,191  | 142,755  | 196     | ND      | 282   | 268,000  |
| Pm12              | 34                          | None      | 681 | 481  | 4.55E+08 | 20,761   | ND      | ND      | 741   | 866,000  |
| Pm13              | 35                          | None      | 390 | 350  | 1.72E+08 | 8.41E+07 | 3,365   | 96,705  | 421   | 1.62E+06 |
| Pm14              | 36                          | None      | 758 | 588  | 8.37E+07 | 1.33E+06 | 1,364   | 586    | 253   | 377,000  |

* The animal was treated with flucloxacillin and paroxetine at day 12 postinoculation.
* The animal was treated with minocycline at 28 days prior to infection.
* The treatments did not affect virus replication or progression of disease. Abbreviations: ND, not detected (the level was below the limit of detection); Pm, pigtailed macaque.
policies and approved by the Johns Hopkins School of Medicine Animal Care and Use Committee.

**Isolation of myeloid cells and lymphocytes from blood and tissues.** Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on a 1.077-g/ml Percoll/Hanks gradient (GE Healthcare, Pittsburgh, PA) according to the manufacturer’s protocol. BAL fluid was obtained by passing 250 ml of sterile saline (Life Technologies, Grand Island, NY) into the lungs via a bronchoscope. BAL fluid cells were isolated by passing the lavage samples through a 183-μm-pore-size sterile mesh. Spleen and lung cells were mechanically removed from tissues using an 18-gauge needle and passed through a 100-μm-mesh-size cell strainer. Brain parenchymal macrophages and microglia were isolated as previously described (41).

Blood, BAL fluid, lung, and spleen macrophages were cultured in RPMI 1640 medium (Life Technologies) supplemented with 20% heat-inactivated human type AB serum (Gemini Bio Products, West Sacramento, CA), 100 U/ml penicillin-streptomycin (Life Technologies), 20 μg/ml gentamicin (Life Technologies), 2 mM L-glutamine (Life Technologies), 2 mM sodium pyruvate (Sigma), 10 mM HEPES buffer (Life Technologies), and 100 U/ml penicillin-streptomycin (Life Technologies) supplemented with 10% heat-inactivated bovine serum (Atlanta Biologicals), 100 U/ml interleukin-2 (IL-2; Novartis, New York, NY). Samples were incubated at 37°C in a humidified 5% CO2 incubator according to the manufacturer’s protocol. The purified macrophages were cultured in Dulbecco modified Eagle medium (Life Technologies) supplemented with 5% heat-inactivated fetal bovine serum (FBS; Atlanta Biologicals), 3 mM sodium pyruvate (Sigma), and 10 mM HEPES buffer (Life Technologies).

CD4+ T cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (Atlanta Biologicals), 100 U/ml penicillin-streptomycin (Life Technologies), 1% T cell growth factor (31), and 100 U/ml interleukin-2 (IL-2; Novartis, New York, NY). Samples were analyzed fresh or frozen vial and rapidly thawed in the corresponding medium prior to cell isolation.

**Mdb-QVOA.** Monocytes and tissue macrophages strongly express the integrin CD11b (42), a common myeloid marker (43–46). Myeloid cells were purified on the basis of expression of CD11b with a nonhuman primate CD11b antibody-conjugated microbead kit (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s protocol. The purified macrophages were cultured in triplicate in a 10-fold limiting dilution in the presence of 10 μM zidovudine (Sigma) and 25 mM darunavir (Janssen, Titusville, NJ) for 3 days for cell attachment or 7 days for differentiation of peripheral blood monocytes. Poly-L-lysine-coated plates (Sigma) were used, and the plates were spun down at 2,000 rpm (872 × g) for 10 min to increase cell adherence. The cells were washed twice with Hank’s balanced salt solution (Life Technologies) to remove nonadherent CD3+ lymphocytes. Medium containing 10 ng/ml recombinant human tumor necrosis factor alpha (TNF-α; ProSpec, East Brunswick, NJ) and 1 × 107 CEMx174 cells/well was added to each well. CEMx174 cells served to expand the virus released from infected cells, as previously described (47). The medium was replenished with TNF-α after 4 days in coculture; supernatants and cell lysates were collected following 12 days of coculture with CEMx174 cells. The presence of replication-competent virus was determined by isolating RNA from the supernatant and measuring the amount of SIV RNA by quantitative reverse transcription-PCR (qRT-PCR).

The frequency of cells harboring replication-competent virus was determined by the use of limiting dilution assay statistics (32) and expressed as the number of infectious units per million (IUPM). The contents of two sets of negative-control wells with CEMx174 cells only were added to the cultures. In addition, to determine the number of CD3+ T cells that were in the assay, the contents of duplicate control wells with CD11b+ macrophages without CEMx174 cells were used to measure the amount of TCRβ RNA, as described below.

**Generation of RNA standards for TCRβ RNA assay.** RNA isolated from macaque CD3+ T cells was reverse transcribed into cDNA using a SuperScript II enzyme kit (Life Technologies) with 4.1 mM MgCl₂, 0.5 mM (each) deoxynucleoside triphosphate, 1 mM dithiothreitol, 150 ng random hexamers, 1× first-strand buffer (provided in kit), and 1 unit of RNaseOUT in a 20-μl reaction mixture. The sample was incubated at 25°C for 15 min, 42°C for 40 min, 85°C for 10 min, and 25°C for 10 min. The resulting cDNA was amplified by PCR using a PCR SuperMix high-fidelity kit (Life Technologies) with TCRβ-specific primers, forward primer 5′-GAG GAC CTG AAA AAG GTG TTC-3′ and reverse primer 5′-CAT AGA GGA TGG TCG CAG ACA-3′, designed to be specific for the constant region of the TCRβ chain of macaques, as previously described (48). The mix was incubated for 30 s at 94°C, followed by 35 cycles of 94°C for 15 s, 50°C for 15 s, and 68°C for 30 s, and was then incubated at 72°C for 10 min. The resulting TCRβ PCR product was cloned into a pCR2.1 TOPO vector and sequenced, and the sequence was confirmed. For in vitro RNA transcription, the plasmid was digested with BamHI, and TCRβ RNA was then generated with a MEGAscript T7 kit (Life Technologies) and used as the control transcript for preparation of the standard curve.

**Quantitation of TCRβ RNA.** TCRβ RNA was quantitated by qRT-PCR using a QuantiTect kit (Qiagen), the above-described primers, and the probe 5′-56-FAM/ACG TCC GTT/ZEN/GCC AAG TCC AGT TCT AT/3IABkFQ-3′ (where 56-FAM is 6-carboxyfluorescin, 3IABkFQ is 3′ Iowa Black FQ, and Zen is an internal quencher [Integrated DNA Technologies, Coralville, Iowa]), based on sequence analyses of macaque TCRβ RNA. Cycling conditions were as follows: 50°C for 30 min, 95°C for 15 min, and 45 cycles of 94°C for 15 s, 55°C for 15 s, and 60°C for 30 s. 18S rRNA was multiplexed with the TCRβ RNA to control for cell counts. To determine the average number of TCRβ copies per CD3+ T cell, PBMCs from seven uninfected macaques were labeled with phycoerythrin (PE)-conjugated anti-CD1 clone SP34 (BD Bioscience, San Jose, CA) and magnetically separated using an EasySep PE positive selection kit (Stemcell Technologies, Vancouver, BC, Canada). The purity of the cells was confirmed by flow cytometry (see Fig. 2A). A minimum of 4 aliquots of a million CD3+ T cells from each macaque was used to isolate RNA that was analyzed by qRT-PCR for TCRβ RNA, and the number of copies of TCRβ RNA per macaque CD3+ T cell was calculated (see Fig. 2B).

**Flow cytometry.** All CD11b+ myeloid cells were labeled with PE-conjugated anti-CD3 clone SP34 (BD Bioscience) and fluorescein isothiocyanate-conjugated anti-CD1b clone B1 (Beckman Coulter, Brea, CA) to assess the selection efficiency. Purified CD4+ T cells were stained with antibodies for HLA-DR clone L243 (BioLegend), CD3 clone SP34-2 (BD Bioscience), CD3 clone OKT4 (BioLegend), CD8 clone RPA-T8 (BioLegend), and TCRβ clone B1.1 (eBioscience). Cells were stained for 20 min at room temperature in 100 μl phosphate-buffered saline–2% FBS and fixed for 10 min with Fix/Lythe buffer (Becton Dickinson, Franklin Lakes, NJ). After fixation, samples were analyzed in a BD LSRFortessa flow cytometer using DIVA software (Becton Dickinson, Franklin Lakes, NJ). The gating of CD3+ T cells was easily visualized as small CD3− nonautofluorescent cells. All data were analyzed using FlowJo software. CD4+ T cell and monocyte counts were analyzed as previously described (38).

**Fluorescence microscopy.** Cocultured live monocyte-derived macrophages were treated at 37°C for 4 h with 10 μM pHrodo Green Escherichia coli bioparticles (Life Technologies), which can be phagocytosed only by functional macrophages and are nonfluorescent at neutral pH but which are fluorescent in the acidic pH of phagosomes (49). The cells were then stained at room temperature for 20 min with 2 drops of 0.1% MucBlue live nuclear marker (Life Technologies), a Hoechst 33342 nuclear marker that emits fluorescence when bound to DNA (50). Images were taken on a Nikon Eclipse TE200 fluorescence microscope and merged using Adobe Photoshop CS4 software (Adobe, San Jose, CA).

**T cell viral outgrowth assay.** Total CD4+ T cells were enriched by use of a nonhuman primate-specific microbead isolation kit (Miltenyi Biotec), which depleted cells expressing CD8, CD11b, CD16, CD20, CD56, and CD66abce. Infected CD4+ T cells were quantified by using a previously described 5-fold limiting dilution assay (34, 35, 47). The cells were

---

**Quantitation of SIV-Infected Myeloid Cells**

on July 22, 2018 by guest
http://jvi.asm.org/
coclutured with CEMx174 cells for 2 weeks. The culture supernatant was analyzed for SIV RNA by qRT-PCR. The frequencies of infected cells were determined by limiting dilution assay statistics (32) and were expressed in terms of the number of IUPM.

**RNA isolation from cells and tissues.** RNA was isolated from cell cultures with an RNeasy Plus minikit (Qiagen, Valencia, CA) according to the manufacturer’s protocol, with modifications. An on-column DNase digestion was performed using an RNase-free DNase kit (Qiagen) with the addition of 4 units of Turbo DNase (Life Technologies) to the enzyme mix. Two hundred microliters of fluid (from CSF, plasma, and culture supernatants) was isolated using a QIAamp MinElute virus spin kit (Qiagen) according to the manufacturer’s protocol, with modifications. An on-column DNase digestion was performed using the RNase-free DNase kit (Qiagen) with the addition of 3 units of RQ1 DNase (Promega, Madison, WI) to the enzyme mix.

Frozen tissues were isolated with RNase STAT-60 (Tel Test Inc., Friendswood, TX) and homogenized with a FastPrep-24 instrument (MP Biomedicals, Santa Ana, CA) in lysing matrix D tubes (MP Biomedicals). The sample was separated with chloroform, and the aqueous phase was treated with isopropanol to precipitate the RNA. The RNA was purified with an RNeasy minikit (Qiagen) with an on-column DNase digestion using the RNase-free DNase kit (Qiagen) and the addition of 3 units of RQ1 DNase (Promega) to the enzyme mix.

**Quantitation of SIV RNA.** SIV RNA was measured by qRT-PCR using a QuantiTect virus kit (Qiagen) and primers specific for the SIV gag region, as previously described (34, 51, 52). Three reactions were performed for each sample. To control for DNA contamination, one reaction was analyzed by use of a reaction mixture without reverse transcriptase. Samples were analyzed with a Rotor-Gene thermocycler (Qiagen).

**PBMC infection.** PBMCs from uninfected pigtailed macaques were isolated by use of a Percoll density gradient and plated in 48-well plates in RPMI 1640 medium supplemented with 2 μg/ml recombinant human IL-2 (Life Technologies) and 2 μg/ml phytohemagglutinin, M form (Life Technologies), overnight. The PBMCs were spinoculated for 2 h with 100 μl supernatants from triplicate independent wells from Mφ-QVOAs with samples from Pm6 and Pm4 (blood, spleen, microglia, and lung). The PBMCs were infected for 5 h at 37°C, the supernatant was removed, and excess virus was washed five times with sterile saline. The medium was replaced and supplemented with 2 μg/ml IL-2 (Life Technologies). Supernatants were collected at days 5, 10, and 13 post-inoculation.

**SIV env sequence analyses.** Supernatant RNA was reverse transcribed into cDNA using a SuperScript III reverse transcriptase enzyme kit (Life Technologies) according to the manufacturer’s protocol. The resulting cDNA was amplified using a Platinum PCR SuperMix high-fidelity kit (Life Technologies), according to the manufacturer’s protocol, with two rounds of nested PCR against SIV env-specific primers. The primer sequences were as follows: for the first round 5’-ARG AAT GCC ACA ATT CCC CT-3’ for the forward primer and 5’-TCC ATC ATY CTT GTG CAT GAA G-3’ for the reverse primer, and for the second round, 5’-CAG TCA CAG AAC AGG CAA TAG A-3’ for the forward primer and 5’-TAA GCA AAG CAT AAC CTG GMG GT-3’ for the reverse primer. In both rounds, amplification was with the same cycling conditions: 94°C for 1 min and then 40 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min. The resulting product was amplified with a DNA Clean & Concentrator-5 kit (Zymo Research) according to the manufacturer’s protocol and sequenced on an Illumina MiSeq sequencer. The sequences were analyzed using Geneious (version 8.0) software (Biomatters, Auckland, New Zealand).

**Statistics.** The frequencies of infected cells in limiting dilution assays were calculated using the IUPMStats (version 1.0) infection frequency calculator (http://silicianolab.johnshopkins.edu) (32). Correlations were computed using a two-tailed nonparametric Spearman rank correlation analysis. Statistical analyses were performed using Prism software (GraphPad Software, La Jolla, CA).

**RESULTS**

**Development of Mφ-QVOAs.** The viral outgrowth assay used to measure productively infected HIV- and SIV-infected resting CD4+ T cells uses highly purified resting CD4+ T cells that are serially diluted and activated with IL-2 (31, 33). To amplify infectious virus produced by CD4+ T cells, susceptible cells of human cell lines (MT4 or CEMx174 cells) are added to each well and the virus in the cell supernatants is quantified by qRT-PCR or enzyme-linked immunosorbent assay (33–35, 47). The frequency of productively infected cells is calculated on the basis of the number of virus- or viral RNA-positive wells or replicates in each of the serial dilutions (32, 33).

Our macrophage quantitative viral outgrowth assay (Mφ-QVOA) was based on the same experimental approach used for the CD4+ T cell QVOA. Monocytes and tissue macrophages strongly express the integrin CD11b (42) and could be separated from other cell types by sorting with CD11b-specific Miltenyi magnetic beads (43–46). The CD11b+ cells were serially diluted, and antiretroviral drugs were added to the culture to prevent virus spread from nonadherent CD4+ T cells. Unlike T cells, macrophages do not divide exponentially when activated in culture and require adherence to culture plates when grown in vitro (53). After the monocytes or macrophages adhered to the culture plate, residual nonadherent T cells were removed from each well (Fig. 1C).

The purity of myeloid cells selected with CD11b-specific beads was assessed by flow cytometry by examining cells that expressed CD3 and CD11b. CD11b+ myeloid cells from blood, BAL fluid, lungs, spleen, and brain from 14 SIV-infected macaques were analyzed. Flow cytometry analyses of PBMCs isolated from blood after CD11b+ cell selection showed that there were <1% CD3+ T cells among the selected cells (Fig. 1A). The percentage of CD11b+ cells selected from tissues ranged from 94% to 99.1% (Fig. 1B). CD11b+ cells adhered to the culture plates, and any residual CD3+ lymphocytes that remained in the culture supernatant did not proliferate (Fig. 2C).

To evaluate the presence of contaminating CD4+ T cells in the macrophage cultures, CD11b+ macrophage control wells without CEMx174 cells were analyzed at 12 days postseeding, the cells were lysed, and TCRβ RNA was quantitated by qRT-PCR. TCRβ RNA is present in macaque CD3+ T cells at an average of 3.8 ± 0.8 copies per cell, as it was determined by qRT-PCR (Fig. 2B).

The number of CD3+ T cells was quantitated prior to CD11b+ cell selection, after CD11b+ selection, and at the end of the Mφ-QVOAs in the control wells without CEMx174 cells (Fig. 2C). On average, at the end of the assay less than 0.9% CD3+ T cells remained among the monocyte-derived macrophages, 0.3% and 1.5% remained among the BAL fluid and lung macrophages, respectively, 2.5% remained among the splenic macrophes, and 0.06% remained among the brain macrophag(300,687),(400,829). Based on the frequency of infection of CD4+ T cells quantitated by the standard QVOA (see Table 3) and the CD4+ T cell percentages in the blood and spleen determined by flow cytometry, we calculated that there was, on average, less than one infected CD4+ T cell in any of the Mφ-QVOAs (Table 2). Therefore, the small number of CD4+ T cells that remained in the wells was not sufficient to contribute to the amount of virus quantitated in the Mφ-QVOAs.

To ensure that SIV gene expression was active in all the infected macrophages, TNF-α, a potent activator of macrophages and the U1 monocytic cell line (54, 55), was added to all wells along
with CEMx174 cells to expand replication-competent viruses. CEMx174 is a T/B cell hybrid line widely used to propagate all strains of SIV, including those used to infect the macaques in this study (47, 56).

Cell supernatants and lysates were isolated separately after 12 days of cocultivation (Fig. 3A). Viral RNA was isolated from cell supernatants from triplicate wells and quantitated individually by qRT-PCR. Wells were considered positive for SIV when RNA levels were higher than 50 copies per 200 μl of supernatant, which was the threshold of detection for the qRT-PCR. The frequency of virus according to the number of infectious units per million (IUPM) was calculated using limiting dilution statistical analyses (32).

To determine the viability of the macrophages cocultured with CEMx174 cells, phagocytosis, a function of viable macrophages, was measured by assessing the number of cells that engulfed pHrodo Green E. coli bioparticles (Fig. 3B). Both CEMx174 cells and macrophages were stained with NucBlue live nuclear stain. The number of cells stained with both markers in each dilution of macrophages reflected the number originally plated. Furthermore, wells with 10^6 CD11b^+ macrophages plated with CEMx174 cells (Fig. 3B, second column) and without CEMx174 cells (Fig. 3B, last column) showed equivalent numbers
of double-labeled cells. This suggests that the macrophages remained viable throughout the Mφ-QVOA, despite the coculture conditions. Finally, Fig. 3B demonstrates that macrophages, unlike lymphocytes, did not expand in culture; therefore, the Mφ-QVOA provides only a minimum estimate of the size of the reservoir.

Quantitation of productively infected myeloid cells and CD4+ T cells in blood and tissues. The SIV Mφ-QVOA was used to quantitate the number of productively infected monocytes in blood and macrophages in the BAL fluid, lungs, spleen, and brain of SIV-infected macaques (Fig. 4). The amount of infected macrophages is an estimate of infection on the basis of the assumption...
that the cells isolated are representative of the population in each
tissue. The frequency of productively infected macrophages in
each tissue varied among the macaques, with the highest number
being found in the spleen (median, 424 IUPM), a secondary lymphoid
tissue that contains both CD4⁺ T cells and tissue-resident
macrophages. A high frequency of productively infected macro-
phages was found in macaques with late-stage disease (>84 dpi)
as well as those with chronic disease (34 to 36 dpi), suggesting that
there is replenishment of infected macrophages throughout
infection due to macrophage turnover. In lung, the numbers of
productively infected interstitial macrophages were also very simi-
lar between the animals with late-stage disease and those with
chronic infection; the number of productively infected interstitial
macrophages was equivalent to the levels in interstitial macrophages
(Fig. 4).

The majority of the CD11b⁺ cells isolated from brain represent
microglia; however, perivascular macrophages, which are mono-
cyte-derived macrophages from blood, also express CD11b. Brain
had the widest range of productively infected microglia/macroph-
ages among all the tissues and between macaques. While spleen
contained the highest number of infected cells, the brains of ani-
mals with mild to severe CNS disease contained the next highest
number of infected cells (median, 231 IUPM). The two macaques
with the most productively infected cells (Pm3 and Pm4, with
24,000 IUPM) had severe encephalitis and high levels of viral RNA
in their brains. The macaques without CNS disease (Pm9
through Pm12) had undetectable numbers of infected micro-
glia/macrophages (Table 3) and little or no detectable viral
RNA in the brain (Table 1). The number of productively in-
ected microglia/macrophages trended toward a correlation with the SIV RNA level in the two regions of the brain with the
highest levels of viral RNA, the basal ganglia (r = 0.71) and
parietal cortex (r = 0.64) (Fig. 5).

Productively infected CD4⁺ T cells in the blood had a median of
206 IUPM, a number almost 10-fold higher than the number
for infected monocytes in blood (34, 35). However, there was no
correlation between the plasma viral load and the frequency of
infected macrophages or lymphocytes in a particular tissue or
blood. The QVOAs provided a means for comparison of the
minimum estimate of the level of productive infection in the
two major SIV target cells. Further, they suggested that macro-
phages are a significant source of virus from tissues during
chronic infection.

**Infectivity and sequence analyses of viruses from Mφ-QVOAs.**

To confirm that virus produced in the Mφ-QVOAs was replica-
compotent, virus-containing supernatants from the Mφ-
QVOAs with blood monocyte-derived macrophages, lungs,
spleens, and brains from SIV-infected macaques Pm4 and Pm6
were used to infect PBMCs isolated from uninfected macaques.
After infection, supernatants from the newly infected PBMCs
were analyzed at multiple time points for SIV RNA by qRT-
PCR. Viral spread was observed in all wells (Fig. 6B), indicating
that virus produced in the Mφ-QVOAs was infectious even when low levels of SIV RNA
were found in the supernatants. This provides evidence that
this novel viral outgrowth assay functions like the CD4⁺ T cell
QVOA.

Sequence analysis of the V1 region of SIV env was performed
with virus isolated from the QVOA wells done with both CD4⁺ T
cells and macrophages from the spleens of SIV-infected macro-
phages. A high frequency of productively infected macro-
phages. A high frequency of productively infected macro-
phages. A high frequency of productively infected macro-
phages were used to infect PBMCs isolated from uninfected macaques.
After infection, supernatants from the newly infected PBMCs
were analyzed at multiple time points for SIV RNA by qRT-
PCR. Viral spread was observed in all wells (Fig. 6B), indicating
that virus produced in the Mφ-QVOAs was infectious even when low levels of SIV RNA
were found in the supernatants. This provides evidence that
this novel viral outgrowth assay functions like the CD4⁺ T cell
QVOA.

Sequence analysis of the V1 region of SIV env was performed
with virus isolated from the QVOA wells done with both CD4⁺ T
cells and macrophages from the spleens of SIV-infected macro-
phages. A high frequency of productively infected macro-
phages were used to infect PBMCs isolated from uninfected macaques.
After infection, supernatants from the newly infected PBMCs
were analyzed at multiple time points for SIV RNA by qRT-
PCR. Viral spread was observed in all wells (Fig. 6B), indicating
that virus produced in the Mφ-QVOAs was infectious even when low levels of SIV RNA
were found in the supernatants. This provides evidence that
this novel viral outgrowth assay functions like the CD4⁺ T cell
QVOA.

Sequence analysis of the V1 region of SIV env was performed
with virus isolated from the QVOA wells done with both CD4⁺ T
cells and macrophages from the spleens of SIV-infected macro-
phages. A high frequency of productively infected macro-
phages were used to infect PBMCs isolated from uninfected macaques.
After infection, supernatants from the newly infected PBMCs
were analyzed at multiple time points for SIV RNA by qRT-
PCR. Viral spread was observed in all wells (Fig. 6B), indicating
that virus produced in the Mφ-QVOAs was infectious even when low levels of SIV RNA
were found in the supernatants. This provides evidence that
this novel viral outgrowth assay functions like the CD4⁺ T cell
QVOA.

Sequence analysis of the V1 region of SIV env was performed
with virus isolated from the QVOA wells done with both CD4⁺ T
cells and macrophages from the spleens of SIV-infected macro-
phages. A high frequency of productively infected macro-
phages were used to infect PBMCs isolated from uninfected macaques.
After infection, supernatants from the newly infected PBMCs
were analyzed at multiple time points for SIV RNA by qRT-
PCR. Viral spread was observed in all wells (Fig. 6B), indicating
that virus produced in the Mφ-QVOAs was infectious even when low levels of SIV RNA
were found in the supernatants. This provides evidence that
this novel viral outgrowth assay functions like the CD4⁺ T cell
QVOA.

Sequence analysis of the V1 region of SIV env was performed
with virus isolated from the QVOA wells done with both CD4⁺ T
cells and macrophages from the spleens of SIV-infected macro-
phages. A high frequency of productively infected macro-
phages were used to infect PBMCs isolated from uninfected macaques.
After infection, supernatants from the newly infected PBMCs
were analyzed at multiple time points for SIV RNA by qRT-
PCR. Viral spread was observed in all wells (Fig. 6B), indicating
that virus produced in the Mφ-QVOAs was infectious even when low levels of SIV RNA
were found in the supernatants. This provides evidence that
this novel viral outgrowth assay functions like the CD4⁺ T cell
QVOA.

See the original document for the table:

**Table 2: Percentages of infected CD4⁺ T cells among macrophages in blood and spleen Mφ-QVOAs**

| Compartment and animal identifier | No. of IUPM in CD4⁺ T cells | % CD3⁺ T cells among CD4⁺ T cells in Mφ-QVOA by TCRβ RNA level | % CD4⁺ T cells among CD3⁺ T cells by flow cytometry | % CD4⁺ T cells in Mφ-QVOA by TCRβ RNA level | No. of IUPM in CD11b⁺ macrophages |
|----------------------------------|-----------------------------|---------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------|
| **Blood**                       |                             |                                                               |                                               |                                               |                                  |
| Pm4                             | 8.08                        | 0.17                                                          | 48                                            | 0.08                                          | 0.0                              | 369.97                          |
| Pm5                             | 40.52                       | 1.27                                                          | 44                                            | 0.56                                          | 0.2                              | 139.38                          |
| Pm6                             | 205.84                      | 2.01                                                          | 32                                            | 0.64                                          | 1.3                              | 23,116.35                       |
| Pm7                             | 71.06                       | 0                                                             | 34                                            | 0                                             | 0                                | 2.07                            |
| Pm8                             | 1,121.51                    | 0.2                                                            | 34                                            | 0                                             | 0                                | <0.1                          |
| Pm9                             | 81.70                       | 2.20                                                          | 31                                            | 0.69                                          | 0.6                              | 45.96                           |
| Pm12                            | 420                         | 0                                                             | 64                                            | 0.69                                          | 0.6                              | 8.48                            |
| Pm13                            | 205.84                      | 1.58                                                          | 32                                            | 0.50                                          | 1.0                              | 16.97                           |
| Pm14                            | 1,121.51                    | 0.31                                                          | 54                                            | 0.17                                          | 1.9                              | 4.62                            |
| **Spleen**                      |                             |                                                               |                                               |                                               |                                  |
| Pm4                             | 40.52                       | 0.36                                                          | 17                                            | 0.06                                          | 0.0                              | 423.93                          |
| Pm5                             | 9.14                        | 6.23                                                          | 23                                            | 1.41                                          | 0.1                              | 854.58                          |
| Pm6                             | 40.52                       | 5.74                                                          | 6                                             | 0.32                                          | 0.1                              | 95,280.33                      |
| Pm9                             | 205.84                      | 2.02                                                          | 9                                             | 0.18                                          | 0.4                              | 23.12                           |

a Pm, pigtail macaque.

b Below the limit of detection.
QVOA and the CD4⁺ T cell QVOA within the spleen of the same macaque was very similar (Fig. 7A). Furthermore, the viruses produced from CD4⁺ T cells and macrophages from three animals also had very similar sequences (Fig. 7B and C). To exclude the possibility of virus selection from coculture with CEMx174 cells, virus isolated from control CD11b⁻/H11001 macrophage wells without CEMx174 cells was also analyzed. Virus from only one macrophage control well had a sequence different from the predominant sequence in the other M/H9278-QVOA wells (Fig. 7). This suggests that coculture with CEMx174 cells did not significantly affect the viruses that replicated and that were detected in the M/H9278-QVOAs.

Further, the similarity of the infectious virus isolated from CD4⁺/H11001 T cells and macrophages in spleen during chronic infection suggests that the SIVs in spleen during this period are dual tropic, infecting both CD4⁺/H11001 T cells and macrophages.

**DISCUSSION**

HIV and SIV infection in tissues and *in vitro* has been widely studied. However, the number of macrophages in tissues and monocytes in blood that harbor replication-competent virus has not been quantitated. In this study, we developed an assay to measure the number of blood monocytes and tissue macrophages that contain replication-competent virus. This assay is based on our previous macaque CD4⁺ T cell QVOA. The assay required an understanding that macrophages require culture conditions for adherence and that they do not undergo exponential expansion like CD4⁺ T cells do. The *in vitro* culture of primary tissue macrophages also required different conditions for each tissue that we studied, unlike isolation of CD4⁺ T cells from blood and tissues. In order to select macrophages from tissues, expression of the CD11b antigen was used since it is uniformly expressed on monocytes and macrophages. In addition, to exclude the contribution of CD4⁺ T cells to this assay, we developed an assay for the detection and quantitation of TCRβ RNA.

Using this Mφ-QVOA, we quantitated the number of macrophages that contained replication-competent virus in the blood, BAL fluid, lung, spleen, and brain of SIV-infected macaques. We demonstrated that macrophages isolated from the blood and from several tissues of SIV-infected macaques harbored replication-competent virus. We also showed that the blood-derived and tissue macrophages used in the Mφ-QVOA had normal phagocytic

*FIG 3* Mφ-QVOA. Monocytes from blood and tissue macrophages from BAL fluid, lung, spleen, and brain were collected from SIV-infected animals and purified by CD11b-specific bead selection. Macrophages expressing CD11b were plated in serial dilutions in triplicate wells. Cells were cultured with zidovudine (AZT) and darunavir (DRV). Nonadherent cells and the antiretrovirals were removed prior to activation with TNF-α and coculture with CEMx174 cells. (A) Schematic of Mφ-QVOA. (B) Live fluorescence microscopy of CD11b⁺ monocyte-derived macrophages cocultured with CEMx174 cells stained with NucBlue live nuclear marker (top row, blue) or pHrodo Green *E. coli* (middle row, green). Merged images are shown in the bottom row. Images were taken on a Nikon Eclipse TE200 microscope. Magnifications, ×10.
function and remained viable throughout the assay, despite prolonged culture and activation with TNF-α. Further, the virus produced by the cells in the Mδ-QVOA was capable of de novo infection of macaque PBMCs. Finally, we characterized the virus isolated from the Mδ-QVOA by analyzing env sequences and virus infectivity in PBMCs. The env sequences from viruses isolated from CD4+ T cell and macrophage QVOAs were not substantially different. All isolated viruses replicated efficiently in PBMCs, suggesting no selection in macrophages for altered virus tropism.

The number of productively infected macrophages in a given tissue was surprisingly similar from macaque to macaque, whereas the number of productively infected macrophages in different tissues from the same SIV-infected macaque varied widely. The nearly 10-fold difference in the number of productively infected monocytes and the number of productively infected CD4+ T cells in blood suggests that monocytes either are less susceptible to SIV infection, have a higher turnover, or harbor more viral genomes that are not replication competent. The highest number of infected macrophages (424 IUPM) was measured in spleen, demonstrating that splenic macrophages are highly susceptible to SIV infection.
infection and harbor high levels of productive genomes. This suggests a role for tissue microenvironments in mediating virus infection of macrophages (57, 58). The populations of macrophages that reside in each tissue may be differentially susceptible to SIV/HIV infection on the basis of the cytokine profiles of the organs (59–61).

It has recently been demonstrated that tissues contain two phenotypically different macrophage populations that are derived

TABLE 3 Macrophage and CD4⁺ T cell IUPM in blood and tissues

| Animal identifierᵃ | CNS score | No. of IUPM in the indicated compartment by: |  |
|-------------------|----------|------------------------------------------|--|
|                   |          | Mb- QVOA                                | CD4⁺ QVOA |
|                   |          | Blood | BAL fluid | Lung | Spleen | Brain | Blood | Spleen |
| Pm1               | Severe   |       |           |      |        |       | 231.16 |        |
| Pm2               | Severe   |       |           |      |        |       | 93.28  |        |
| Pm3               | Severe   |       |           |      |        |       | 23,978.95 |        |
| Pm4               | Severe   | 369.97 | 1,481.48  | 1,838.35 | 423.93 |       | 23,116.35 |     |
| Pm5               | Mild     | 139.38 | 57.79     | 46.23  | 854.58  | 427.29 | 8.08   | 40.52  |
| Pm6               | None     | 23,116.35 | 18.38  | 46.07  | 93,280.33 | 42.39 | 205.84 | 40.52  |
| Pm7               | None     | 2.07   |           |       |         |       | 71.06  | 81.70  |
| Pm8               | None     | <0.1ᵇ  |           |       |         |       | 1,121.51 | 205.84 |
| Pm9               | None     | 45.96  | 1.81      | <1.0ᵇ  | 23.12   | <0.42ᵇ | 81.70  | 205.84 |
| Pm10              | None     |       |           | <2.31ᵇ |         |       |        |        |
| Pm11              | None     |       |           | <1.05ᵇ |         |       |        |        |
| Pm12              | None     | 8.48   | <1.0ᵇ     | 11.56  | 57.79   | <0.2ᵇ  | 420    |        |
| Pm13              | None     | 16.97  | 8.48      | 18.38  | 462.33  | 231.16 | 205.84 |        |
| Pm14              | None     | 4.62   | 4.62      | 9.19   | 313.67  | 42.42  | 1121.51 |        |

ᵃ Pm, pigtail macaque.
ᵇ Below the limit of detection.

FIG 6 Virus produced in Mb-QVOAs is replication competent. Supernatant was collected from the blood Mb-QVOA (A), lung Mb-QVOA (B), spleen Mb-QVOA (C), and brain Mb-QVOA (D) for Pm4 (filled symbols) and Pm6 (open symbols) and used to infect freshly isolated PBMCs by spinoculation. The amount of SIV RNA in the supernatant was measured by qRT-PCR prior to infection (input virus) and longitudinally for 13 dpi. SIV RNA levels are presented as the number of copies per 200 μL. Red symbols, wells whose input virus was undetectable.
FIG 7  Sequence analyses of virus produced in CD4⁺ T cell and macrophage QVOAs. Supernatant was collected from the spleen Mφ-QVOA and spleen T cell QVOA for Pm4, Pm5, and Pm6. Viral RNA was isolated, and a two-round nested PCR for SIV env was performed. CD11b⁺ macrophage wells without CEMx174 cells from the Mφ/QVOA were used as controls. The most frequent (red) and the second most frequent (black) sequences are depicted along with the frequency of the viral clone (indicated in parentheses). (A and B) A tree of the nucleotide sequence alignment for each animal (A) and a phylogenetic tree of all clones (B) are shown. (C) Comparison of the nucleotide sequences of the prevailing clones with the consensus sequence, with percentages signifying the frequency of the clones. The scale bar represents the distance between the sequences. Analyses were performed by Geneious (version 8.0) software.
from either resident (i.e., fetus-derived) macrophages or mono-
cyte-derived macrophages that enter tissues from the bloodstream
(62, 63). There are many indications that both types of macro-
phages harbor persistent virus after suppression of the infection
with ART. For example, some HIV-infected patients have a com-
pletely controlled plasma viral load yet have detectable virus in the
CSF, and some of these patients have accompanying CNS symp-
toms (64, 65). HIV and SIV infection in brain is predominantly in
resident microglia and perivascular macrophages (66–68). In
addition, lung inflammation is ongoing in some patients on ART in
which HIV infection is suppressed, in part due to infected tissue
macrophages (69, 70). ART suppression of virus replication at all
stages of disease likely leads to the persistence of infected myeloid
cells in tissues. The Mb-QVOA that we have developed can be
used for human monocytes and macrophages, and the TCRβ
RNA qRT-PCR assay can detect transcripts from both human and
macaque CD3+ T cells. The Mb-QVOA will be important for
measuring the number of myeloid cells in the tissues of SIV-in-
fected macaques and HIV-infected individuals on ART in which
infection is suppressed.

We have previously reported a significant correlation between
CNS pathology and an elevated CSF viral load but not an elevated
plasma viral load (38); this has also been reported in HIV-infected
individuals with CNS encephalitis prior to ART (71). Quantita-
tion of productively infected macrophages in the brain using the
Mb-QVOA strongly supports the hypothesis that CD11b+ micro-
glia/macrophages in the brain are the major contributors to CNS
infection since a trend toward a correlation between the number
of infected macrophages in both the basal ganglia and parietal
cortex of the brain with viral RNA levels but not the plasma viral
load was found. It is important to note that even in a model with a
high prevalence of CNS pathology similar to that in human dis-
ease, not all of the macaques in this study developed severe CNS
disease. However, those that did develop mild–severe CNS disease
had the highest frequency of infected macrophages in the brain.
This study suggests that the frequency of infection of macrophages
in the brain is directly correlated with and leads to CNS pathology.

In this study, both blood and tissue from untreated SIV-in-
fected macaques were analyzed because the numbers of produc-
tively SIV-infected myeloid cells and CD4+ T cells in tissues dur-
ing infection have not previously been measured. Our results
establish that productively infected tissue macrophages can be
quantitated, that the virus produced is infectious, and that there is
no TCRβ RNA detectable in the infected macrophages. A recent
report concluded that tissue macrophages in SIV-infected maca-
ques contained SIV DNA from phagocytosis of CD4+ T cells
and that tissue macrophages were not a major source of virus in
vivo (72). In sharp contrast, we developed novel optimized meth-
ods for the isolation and evaluation of tissue macrophages, to
demonstrate clearly that SIV-infected tissue macrophages pro-
duce abundant replication-competent virus. Of note, these novel
assays provide a minimum estimate of the amount of productively
infected CD4+ T cells and myeloid cells in SIV-infected tissues in
vivo. It is possible that phagocytized CD4+ T cells infect macro-
phages in vivo, as it has been demonstrated in vitro (73), although
a recent study using mouse models has indicated that macro-
phages can sustain replication in vivo independently of T cells
(74). Using our techniques, it will now be possible to quantify the
number of latently infected CD4+ T cells and persistently infected
myeloid cells that harbor replication-competent virus in SIV-in-
fected macaques in which infection is suppressed by ART to ad-
vance our understanding of HIV latency.

ACKNOWLEDGMENTS
We thank Jeanne Sisk for assistance and the Johns Hopkins School of
Medicine Retrovirus Laboratory for technical assistance and guidance.
We declare no conflict of interest.

This study was supported by NCCR and the Office of Research Infra-
structure Programs (ORIP) of the NIH (grant P40 OD013117) and NIH
funds. This work, including the efforts of Joseph L. Mankowski, M.
Christine Zink, Lucio Gama, and Janice E. Clements, was funded by HHS | National Institutes of
Health (NIH) (R01 HS077869). This work, including the efforts of Janice E. Clements and Joseph L. Mankowski, was funded by NIH | National Institutes of
Health (NIH) (R01 NS077869). This work, including the efforts of Janice E. Clements and Lucio Gama, was funded by HHS | National Institutes of
Health (NIH) (R01 NS076357, U19 AI076113, and R56 AI118753).

FUNDING INFORMATION
This work, including the efforts of Joseph L. Mankowski, was funded by
HHS | National Institutes of Health (NIH) (P40 OD013117). This work, including the efforts of Joseph L. Mankowski, M. Christine Zink, Lucio
Gama, and Janice E. Clements, was funded by HHS | National Institutes of
Health (NIH) (P01 MH070306). This work, including the efforts of Janice E. Clements and Joseph L. Mankowski, was funded by HHS | National Institutes of
Health (NIH) (R01 NS077869). This work, including the efforts of Janice E. Clements and Lucio Gama, was funded by HHS | National Institutes of
Health (NIH) (R01 NS076357, U19 AI076113, and R56 AI118753).

REFERENCES
1. Gendelman HE, Narayan O, Molineaux S, Clements JE, Ghotbi Z. 1985.
Slow, persistent replication of lentiviruses: role of tissue macrophages and
macrophage precursors in bone marrow. Proc Natl Acad Sci U S A 82:
7086–7090. http://dx.doi.org/10.1073/pnas.82.20.7086.
2. Cheever WP, McGuire TC. 1985. Equine infectious anemia virus: im-
munopathogenesis and persistence. Rev Infect Dis 7:83–88. http://dx.doi.
org/10.1093/clinids/7.1.83.
3. Ho DD, Rota TR, Hirsch MS. 1986. Infection of monocyte/macrophage
by human T lymphotropic virus type III. J Clin Invest 77:1712–1715.
http://dx.doi.org/10.1172/JCI112491.
4. Lifson JD, Feinberg MB, Reyes GR, Rabin L, Banapour B, Chakrabarti
S, Moss B, Wong-Staal F, Steimer KS, Engleman EG. 1986. Induction of
CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.
Nature 323:725–728. http://dx.doi.org/10.1038/323725a0.
5. Gallo RC. 1991. Human retroviruses: a decade of discovery and link with
human disease. J Infect Dis 164:235–243. http://dx.doi.org/10.1093/infdis.
164.2.235.
6. Chiu IM, Yaniv A, Dahlberg JE, Gazit A, Skuntz SF, Tronick SR, Aaronson
SA. 1985. Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses. Nature 317:366–368. http://dx.doi.org/10.
3082/317366a0.
7. Haase AT. 1986. Pathogenesis of lentivirus infections. Nature 322:130–
136. http://dx.doi.org/10.1038/322130a0.
8. Kelly KM, Tarwater PM, Karper JM, Bedja D, Queen SE, Tunin RS,
Adams RJ, Kass DA, Mankowski JL. 2012. Diastolic dysfunction is
associated with myocardial viral load in simian immunodeficiency virus-
fected macaques. AIDS 26:815–823. http://dx.doi.org/10.1097/QAD.
0b013e3283518f01.
9. Laast VA, Shim B, Johanek LM, Dorsey JL, Hauer PE, Tarwater PM,
Adams RJ, Pardo CA, McArthur JC, Ringkamp M, Mankowski JL. 2011.
Macrophage-mediated dorsal root ganglion damage precedes altered
nerve conduction in SIV-infected macaques. Am J Pathol 179:2327–2345.
http://dx.doi.org/10.1016/j.ajpath.2011.07.047.
10. Babas T, Vieler E, Hauer DA, Adams RJ, Tarwater PM, Fox K, Cle-
ments JE, Zink MC. 2001. Pathogenesis of SIV pneumonia: selective
replication of viral genomes in the lung. Virology 287:371–381. http://dx.
doi.org/10.1006/viro.2001.1043.
11. Zink MC, Clements JE. 2002. A novel simian immunodeficiency virus
model that provides insight into mechanisms of human immunodefi-
cency virus central nervous system disease. J Neurovirol 8(Suppl 2):
S42–S48.
22. Ribeiro M, Jr, Arnaout M, Hoxie JA, Williams KC, Desrosiers RC, Gabuzda D, 2003. Rapid quantification of the latent reservoir for human immunodeficiency virus-1. J Virol 77:4938–4949. http://dx.doi.org/10.1128/JVI.77.8.4938-4949.2003.

23. Zink MC, Spelman JP, Robinson RB, Clements JE. 1998. SIV infection of macaques—modeling the progression to AIDS dementia. J Neurovirol 4:249–259. http://dx.doi.org/10.1038/sj.jn.11001452.

24. Zink MC, Suranyakanra K, Mankowski JL, Shen A, Piatak M, Jr, Spelman JP, Carter DL, Adams RJ, Linfo JD, Clements JE. 1999. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 73:10480–10488.

25. Zink MC, Dewitt JB, Mankowski JL, Tarwater PM, Clements JE, Zink MC. 2006. Progressive selection for neurovirulent genotypes in the brain of SIV-infected macaques. AIDS 20:197–205. http://dx.doi.org/10.1097/01.aids.0000189078.24584.21.

26. Meulendyke KA, Queen SE, Engle EL, Shirck EN, Liu J, Steiner JP, Nath A, Tarwater PM, Graham DR, Mankowski JL, Zink MC. 2014. Combination fluorozonolide paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease. J Neurovirol 20:591–602. http://dx.doi.org/10.1007/s13365-014-0283-1.

27. Babas T, Munoz D, Mankowski JL, Tarwater PM, Clements JE, Zink MC. 2003. Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain. J Virol 77:208–216. http://dx.doi.org/10.1128/JVI.77.6.208-216.2003.

28. Arnaout MA. 1990. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75:1037–1050.

29. Harms AS, Tansey MG. 2013. Isolation of murine postnatal brain microglia for phenotypic characterization using magnetic cell separation technology. Methods Mol Biol 1041:33–39. http://dx.doi.org/10.1007/978-1-62703-520-0_5.

30. Mink J, Caruso M, Rostami A, Grinspan JB, Das Sarma J. 2008. Magnetic cell sorting: a fast and effective method of concurrent isolation of high purity viable astrocytes and microglia from neonatal mouse brain tissue. J Neurosci Methods 175:108–118. http://dx.doi.org/10.1016/j.jneurosci.2008.08.016.

31. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen MC, Otten GR, Ulmer JB, Donnelly JJ, Ott G, McDonald DM. 2000. Distri-
bution of DNA vaccines determines their immunogenicity after intramus- 
lar injection in mice. J Immunol 165:2850–2858. http://dx.doi.org/10 .4049/jimmunol.165.5.2850.

46. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. 2009. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284:34342–34354. http://dx.doi.org/10.1074/jbc.M109.042671.

47. Shen A, Yang HC, Zhou Y, Chase AJ, Boyer JD, Zhang H, Margolick JB, Zink MC, Clements JE, Siliciano RF. 2007. Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol 81:1660–1670. http://dx.doi.org/10.1128/JVI.01396-06.

48. Smith MJ, Asher TE, Venturi V, Davenport MP, Douek DC, Price DA, Kent SJ. 2008. Limited maintenance of vaccine-induced simian immunodeficiency virus-specific CD8 T-cell receptor chimeras after virus challenge. J Virol 82:7357–7368. http://dx.doi.org/10.1128/JVI.00607-08.

49. Miksa M, Komura H, Wu R, Shah KG, Wang P. 2009. A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. J Immunol Methods 342:71–77. http://dx.doi.org/10.1016/j.imeth.2008.11.019.

50. Kilgore JA, Dolman NJ, Davidson MW. 2013. A review of reagents for fluorescence microscopy of cellular compartments and structures. Part II. Reagents for non-vascular organelles. Curr Protoc Cytom 66:Unit 12.31. http://dx.doi.org/10.1002/0471092596.cyto12166.

51. Gama I, Shirk EN, Russell JN, Carvalho KI, Li M, Queen SE, Kalil J, Zink MC, Clements JE, Kallas EG. 2012 Expansion of a subset of CD14highCD16lowCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection. J Leukoc Biol 91:803–816. http://dx.doi.org/10.1189/jlb.1111157.

52. Meulendyke KA, Pletnikov MV, Engle EL, Tarwater PM, Graham DR, Zink MC. 2012. Early mycinocide treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease. J Neuroimmune Pharmacol 7:454–464. http://dx.doi.org/10.1007/s11418-011-9332-1.

53. Martinez FO, Gordon S, Locati M, Mantovani A. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 177:7730–7731. http://dx.doi.org/10.4049/jimmunol.177.7730.

54. Fernandez G, Zaikos TD, Khan SZ, Jacob AM, Behlke MA, Zeichner SL. 2013. Targeting IkappaB proteins for HIV latency activation: the role of individual IkappaB and NF-kappaB proteins. J Virol 87:3966–3978. http://dx.doi.org/10.1128/JVI.03251-12.

55. Gallastegui E, Marshall B, Vidal D, Sanchez-Duffhues G, Collado JA, Alvarez-Fernandez C, Luque N, Terme JM, Wahl A, Baker C, Spagnuolo RA, Foster J, Zakharova O, W-K, Alvarez X, Fisher J, Bronfin B, Westmoreland S, McLaurin A, Genest L, Everitt A, Winston A, Benzie A. 2006. Transcriptional and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am J Pathol 168:822–834. http://dx.doi.org/10.2333/ajpath.2006.050215.

56. Cosenza MA, Zhao M-L, Si Q, Lee SC. 2002. Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol 12:442–455. http://dx.doi.org/10.1111/j.1750-3639.2002.tb00461.x.

57. Agostini C, Sancetta R, Curutti A, Semenzato G. 1995. Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. J Leukoc Biol 58:495–500.

58. Crothers K, Thompson BW, Burkhardt K, Morris A, Flores SC, Diaz PT, Chaisson RE, Kirk GD, Rom WN, Huang L, Lung HIV Study. 2004. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid. J Neuroimmunol 1443–1444. http://dx.doi.org/10.1097/00134849-200409010-00005.

59. Ortiz A, DiNapoli SR, Brenchley JM. 2015. Macrophages are phenotypically and functionally diverse across tissues in simian immunodeficiency virus-infected and uninfected Asian macaques. J Virol 89:5883–5894. http://dx.doi.org/10.1128/JVI.00005-15.

60. Garvey LJ, Evertt A, Winston A, Mackie NE, Benzie A. 2009. Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment. AIDS 23:1443–1444. http://dx.doi.org/10.1097/QAD.0b013e3282d077c.

61. Cassol E, Cassella L, Alfano M, Poli G. 2010. Macrophage polarization and HIV-1 infection. J Leukoc Biol 87:599–608. http://dx.doi.org/10 .1189/jlb.1009673.

62. Cai Y, Sugimoto C, Liu DX, Midkiff CC, Alvarez X, Lackner AA, Kim WK, Didier ES, Kuroda MJ. 2015 Increased monocyte turnover is associated with intrastitial macrophage accumulation and pulmonary tissue damage in SIV-infected rhesus macaques. J Leukoc Biol 97:1147–1153. http://dx.doi.org/10.1189/jlb.A0914-441R.